Stockscreener 앱 받기
13.07
3.57%
0.45
시간 외 거래:
13.10
0.03
+0.23%
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Intellia Gears Up to Report Q3 Earnings: What's in the Cards? - Zacks Investment Research
Is Intellia Therapeutics Inc. still worth holding after the dipInflation Watch & Verified Short-Term Trading Plans - newser.com
Chart overlay techniques for tracking Intellia Therapeutics Inc.2025 Historical Comparison & Accurate Intraday Trade Tips - newser.com
How sentiment analysis helps forecast Intellia Therapeutics Inc.Market Growth Report & Growth Oriented Trade Recommendations - newser.com
AlphaQuest LLC Sells 29,619 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Real time scanner hits for Intellia Therapeutics Inc. explainedQuarterly Trade Summary & Weekly Chart Analysis and Trade Guides - newser.com
How Intellia Therapeutics Inc. stock reacts to oil pricesEarnings Performance Report & Real-Time Chart Breakout Alerts - newser.com
How cyclical is Intellia Therapeutics Inc. (38I) stock compared to rivalsJuly 2025 WrapUp & Weekly Watchlist of Top Performers - newser.com
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130% - sharewise.com
Should You Buy Viking Therapeutics Before Nov. 5? - AOL.com
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130% - The Motley Fool
Is Intellia Therapeutics Inc. (38I) stock a buy on weakness2025 Momentum Check & Stock Portfolio Risk Management - newser.com
Can a trend reversal in Intellia Therapeutics Inc. lead to recoveryJuly 2025 Breakouts & AI Enhanced Trade Execution Alerts - newser.com
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Is Intellia Therapeutics Inc. (38I) stock trading at attractive multiples2025 Dividend Review & Short-Term High Return Ideas - newser.com
Will Intellia Therapeutics Inc. (38I) stock benefit from sector leadershipWeekly Profit Summary & Long-Term Capital Growth Strategies - newser.com
Relative strength of Intellia Therapeutics Inc. in sector analysisTrade Signal Summary & AI Forecasted Entry/Exit Points - newser.com
Intellia Therapeutics (NTLA) Is Down 50.7% After FDA Halts MAGNITUDE Trials on Safety Concerns – Has The Bull Case Changed? - Sahm
Leerink Partnrs Has Positive Estimate for NTLA Q3 Earnings - MarketBeat
What to expect from Intellia Therapeutics Inc. in the next 30 days2025 Analyst Calls & Momentum Based Trading Signals - newser.com
Intellia Therapeutics Inc. (NTLA) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Intellia Stock Downgraded After Trial Pause Raises Safety Concerns, BofA Says - MarketScreener
SA analyst upgrades/downgrades: AMZN, NVDA, CMG, NTLA - Seeking Alpha
Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a Rare Disease - MedCity News
Intellia Therapeutics: Irreversible Edit Vs. Reversible SOCs Now A Hard Sell (Rating Downgrade) - Seeking Alpha
Gene-editing stocks rally on Bloomberg report that FDA plans to fast-track approval process - Sherwood News
FDA Clears Way for Faster Personalized Gene Editing Therapy - Bloomberg.com
NTLA FY2027 EPS Reduced by Brookline Capital Management - MarketBeat
What is Leerink Partnrs' Estimate for NTLA FY2027 Earnings? - MarketBeat
Is a relief rally coming for Intellia Therapeutics Inc. holders2025 Retail Activity & Free Real-Time Market Sentiment Alerts - newser.com
Analyzing drawdowns of Intellia Therapeutics Inc. with statistical tools2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
What technical models suggest about Intellia Therapeutics Inc.’s comeback2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
Will Intellia Therapeutics Inc. stock benefit from AI adoptionJobs Report & Growth Oriented Trading Recommendations - newser.com
Is Intellia Therapeutics Inc. stock oversold or undervaluedMarket Volume Summary & Free Technical Pattern Based Buy Signals - newser.com
Intellia Therapeutics Faces FDA Clinical Hold on Trials - The Globe and Mail
Intellia: Moving To 'Hold' Rating In Light Of Nex-Z Uncertainty In ATTR Patients (Downgrade) - Seeking Alpha
NTLA Stock: Plummet Unlocks Market Debate? - StocksToTrade
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 7.9% on Analyst Downgrade - MarketBeat
HC Wainwright & Co. Lowers NTLA Price Target to $18, Maintains B - GuruFocus
FDA places formal hold on two Intellia CRISPR trials - BioPharma Dive
FDA puts two Intellia CRISPR trials on hold following liver toxicity case - Endpoints News
Intellia Therapeutics (NASDAQ:NTLA) Lowered to "Hold" Rating by Wells Fargo & Company - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Rating Lowered to Sector Perform at Royal Bank Of Canada - MarketBeat
Life-Threatening Liver Toxicity Triggers FDA Freeze on Two Intellia Gene Therapy Studies - BioSpace
FDA places Intellia phase 3 CRISPR trials on hold over raised liver enzymes - Fierce Biotech
Biotech might be tiny but the dealmaking is mighty - statnews.com
0.64%
0.35%
자본화:
|
볼륨(24시간):